See more : Adyen N.V. (ADYEN.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Acceleron Pharma Inc. (XLRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acceleron Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Grande Armee Investissement SA (MLGAI.PA) Income Statement Analysis – Financial Results
- Clariane SE (CLARI.PA) Income Statement Analysis – Financial Results
- Santova Limited (SNV.JO) Income Statement Analysis – Financial Results
- Pinnacle Bankshares Corporation (PPBN) Income Statement Analysis – Financial Results
- Alimentation Couche-Tard Inc. (ATD.TO) Income Statement Analysis – Financial Results
Acceleron Pharma Inc. (XLRN)
About Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 173.92M | 153.95M | 103.90M | 89.73M | 68.58M | 58.40M | 50.90M | 36.05M | 35.32M | 32.71M |
| General & Administrative | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Other Expenses | 85.91M | 56.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 40.86M |
| Cost & Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 42.36M |
| Interest Income | 2.87M | 10.71M | 5.57M | 2.55M | 1.85M | 512.00K | 83.00K | 39.00K | 91.00K | 17.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 922.00K | 2.09M | 1.53M | 1.82M |
| Depreciation & Amortization | 3.85M | 3.94M | 3.75M | 2.83M | 1.68M | 1.18M | 1.12M | 915.00K | 1.29M | 3.13M |
| EBITDA | -162.16M | -120.98M | -115.15M | -105.60M | -55.31M | -62.72M | -49.22M | -18.89M | -29.76M | 41.22M |
| EBITDA Ratio | -175.27% | -163.50% | -823.04% | -783.30% | -199.18% | -346.57% | -336.38% | -33.01% | -195.10% | 50.95% |
| Operating Income | -167.31M | -136.45M | -124.41M | -109.98M | -66.11M | -60.88M | -50.46M | 6.95M | -28.89M | 38.56M |
| Operating Income Ratio | -180.83% | -184.40% | -889.24% | -815.84% | -238.04% | -336.40% | -344.89% | 12.15% | -189.39% | 47.65% |
| Total Other Income/Expenses | 1.30M | 11.53M | 5.52M | 1.56M | 9.12M | -3.02M | -795.00K | -28.85M | -3.69M | -2.29M |
| Income Before Tax | -166.01M | -124.92M | -118.90M | -108.42M | -56.99M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Income Before Tax Ratio | -179.42% | -168.83% | -849.82% | -804.26% | -205.21% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| Income Tax Expense | 21.00K | -62.00K | -27.00K | 32.00K | 24.00K | -3.02M | 127.00K | -26.76M | -2.16M | -468.00K |
| Net Income | -166.03M | -124.86M | -118.87M | -108.45M | -57.01M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Net Income Ratio | -179.45% | -168.74% | -849.62% | -804.50% | -205.30% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| EPS | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.73 |
| EPS Diluted | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.58 |
| Weighted Avg Shares Out | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 20.95M |
| Weighted Avg Shares Out (Dil) | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 22.97M |
Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International Conference.
Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) preliminary...
Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) interim results...
Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the...
Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19,...
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021. “Acceleron made...
Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol...
Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results. The webcast will be accessible under "Events...
Source: https://incomestatements.info
Category: Stock Reports